Bright Minds Biosciences (DRUG) Operating Expenses (2020 - 2026)

For the quarter ending Q1 2026, Operating Expenses fell 497.68% year-over-year to -$9.6 million, compared with a TTM value of -$7.2 million through Mar 2026, down 397.68%, and an annual FY2025 reading of $10.0 million, up 381.22% over the prior year.

Bright Minds Biosciences (DRUG) has disclosed Operating Expenses for 2 consecutive years, with -$9.6 million as the latest value for Q1 2026.

  • Operating Expenses reached -$9.6 million in Q1 2026 per DRUG's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.4 million in Q1 2025 and bottomed at -$9.6 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 2.97 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 4.33 Mn
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -138.30 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 15.76 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 1.85 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 2.96 Bn
8 Evaxion A 65.12 Bn 65.10 Bn - -3.82 Mn
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 898.54 Mn
10 Bright Minds Biosciences 464.72 Mn 405.19 Mn - -9.59 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -9.59 Mn
Dec 31, 2025 -6.01 Mn
Sep 30, 2025 16.81 Mn
Jun 30, 2025 -4.31 Mn
Mar 31, 2025 -2.41 Mn
Dec 31, 2024 32,422.24
Sep 30, 2024 571,377.01
Jun 30, 2024 157,133.80
Mar 31, 2024 426,077.62
Dec 31, 2023 951,047.22
Sep 30, 2023 779,792.73
Jun 30, 2023 873,040.99
Mar 31, 2023 1.14 Mn
Dec 31, 2022 1.12 Mn
Sep 30, 2022 2.03 Mn
Jun 30, 2022 1.68 Mn
Mar 31, 2022 3.01 Mn
Dec 31, 2021 3.22 Mn
Sep 30, 2021 1.83 Mn
Jun 30, 2021 2.25 Mn
Mar 31, 2021 845,067.11
Dec 31, 2020 291,624.21
Sep 30, 2020 215,917.90